Literature DB >> 15096405

Executive dysfunction in Alzheimer disease.

Margaret M Swanberg1, Rochelle E Tractenberg, Richard Mohs, Leon J Thal, Jeffrey L Cummings.   

Abstract

BACKGROUND: Executive dysfunction (EDF) is common in Alzheimer disease (AD); however, its relationship to other symptoms is difficult to assess in patients with AD.
OBJECTIVES: To determine the prevalence of EDF and study its relationship to cognitive, functional, and neuropsychiatric symptoms in patients with AD. DESIGN, SETTING, AND PATIENTS: A retrospective analysis of data from participants in the English Instruments Protocol of the Alzheimer's Disease Cooperative Study. Subjects were drawn from a sample of patients evaluated at tertiary referral centers.
RESULTS: A total of 64% of AD patients were classified as having EDF. Patients with EDF performed worse on tests of cognition (P <.001), dementia severity (P <.001), and activities of daily living (P =.01) and had more frequent symptoms of psychosis (P =.03) with greater emergence during the 12-month interval (P =.03) compared with patients with normal executive function. Less than 30% of the variance in executive function performance was explained by cognitive measures.
CONCLUSION: These findings support the assessment of executive function in persons with AD and the importance of frontal lobe dysfunction in AD.

Entities:  

Mesh:

Year:  2004        PMID: 15096405      PMCID: PMC4419376          DOI: 10.1001/archneur.61.4.556

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  35 in total

1.  Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease.

Authors:  D G Harwood; W W Barker; R L Ownby; R Duara
Journal:  Int J Geriatr Psychiatry       Date:  2000-05       Impact factor: 3.485

2.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

3.  Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Authors:  R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  Executive dysfunction in early Alzheimer's disease.

Authors:  G Binetti; E Magni; A Padovani; S F Cappa; A Bianchetti; M Trabucchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

5.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

6.  Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease.

Authors:  S Tekin; M S Mega; D M Masterman; T Chow; J Garakian; H V Vinters; J L Cummings
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

7.  Cerebral correlates of psychotic symptoms in Alzheimer's disease.

Authors:  M S Mega; L Lee; I D Dinov; F Mishkin; A W Toga; J L Cummings
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

8.  Hallucinations, delusions, and cognitive decline in Alzheimer's disease.

Authors:  R S Wilson; D W Gilley; D A Bennett; L A Beckett; D A Evans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

Review 9.  Frontal-subcortical circuits and human behavior.

Authors:  J L Cummings
Journal:  Arch Neurol       Date:  1993-08

10.  Functional status and clinical findings in patients with Alzheimer's disease.

Authors:  S Freels; D Cohen; C Eisdorfer; G Paveza; P Gorelick; D J Luchins; R Hirschman; J W Ashford; P Levy; T Semla
Journal:  J Gerontol       Date:  1992-11
View more
  33 in total

Review 1.  [Innovation in diagnostics-mobile technologies].

Authors:  Emrah Düzel; Jochen René Thyrian; David Berron
Journal:  Nervenarzt       Date:  2019-09       Impact factor: 1.214

2.  Apolipoprotein E ε2 and functional decline in amnestic mild cognitive impairment and Alzheimer disease.

Authors:  Aaron Bonner-Jackson; Ozioma Okonkwo; Geoffrey Tremont
Journal:  Am J Geriatr Psychiatry       Date:  2012-07       Impact factor: 4.105

3.  Executive function: Responses to aerobic exercise in Alzheimer's disease.

Authors:  Fang Yu; David M Vock; Terry R Barclay
Journal:  Geriatr Nurs       Date:  2017-10-12       Impact factor: 2.361

4.  Differential Regional Distribution of Juxtacortical White Matter Signal Abnormalities in Aging and Alzheimer's Disease.

Authors:  Emily R Lindemer; Douglas N Greve; Bruce Fischl; Jean C Augustinack; David H Salat
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 5.  Early-Onset Alzheimer Disease.

Authors:  Mario F Mendez
Journal:  Neurol Clin       Date:  2017-05       Impact factor: 3.806

6.  Cognitive dysfunction with aging and the role of inflammation.

Authors:  Arthur A Simen; Kelly A Bordner; Mark P Martin; Lawrence A Moy; Lisa C Barry
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

7.  Language dysfluencies in females with the FMR1 premutation.

Authors:  Audra M Sterling; Marsha Mailick; Jan Greenberg; Steven F Warren; Nancy Brady
Journal:  Brain Cogn       Date:  2013-03-20       Impact factor: 2.310

8.  "Pre-semantic" cognition revisited: critical differences between semantic aphasia and semantic dementia.

Authors:  Elizabeth Jefferies; Timothy T Rogers; Samantha Hopper; Matthew A Lambon Ralph
Journal:  Neuropsychologia       Date:  2010-01       Impact factor: 3.139

9.  Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism.

Authors:  Thaddeus J Haight; Susan M Landau; Owen Carmichael; Christopher Schwarz; Charles DeCarli; William J Jagust
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

Review 10.  The paradox of syndromic diversity in Alzheimer disease.

Authors:  Jason D Warren; Phillip D Fletcher; Hannah L Golden
Journal:  Nat Rev Neurol       Date:  2012-07-17       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.